Surgical treatment of breast cancer liver metastases - a nationwide registry-based case control study
ConclusionSurgery for BCLM is safe and might provide a survival benefit in selected patients but prospective trials are warranted to avoid selection bias.
There is an urgent need to share expertise and offer emergency guidance for breast radiation therapy (RT) during the COVID-19 (Coronavirus) pandemic. As per the World Health Organisation (WHO) statement, our aim and obligation should be “to stop, contain, control, delay and reduce the impact of this virus at every opportunity”. In our roles as healthcare professionals and/or breast cancer experts this translates to minimising exposure of our patients to COVID-19 without compromising oncological outcome.
British Journal of Cancer, Published online: 31 March 2020; doi:10.1038/s41416-020-0816-8Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study
British Journal of Cancer, Published online: 31 March 2020; doi:10.1038/s41416-020-0784-zSurvival and disease characteristics of de novo versus recurrent metastatic breast cancer in a cohort of young patients
Dr. Laura Mulvey, 33, practices emergency medicine at Maimonides Medical Center in Brooklyn, New York. After spending six days receiving treatment in her own hospital, she is now recovering at home from what is presumed to be COVID-19, though her test was inconclusive. What follows is a lightly-edited transcript of her story as told to TIME. Early on, sometime in February, [COVID-19] was something that people were thinking about. And worried about. Certainly, the worries were not what they are now. But hospital-wise, we had a bit of an earlier jump on it, because we recognized that this was a potential threat. We’re ...
Condition: Malignant Neoplasm of Breast Interventions: Drug: Saline; Drug: Ropivacaine Sponsor: Institut Curie Not yet recruiting
(JAMA Network) Nearly 200 radiologists who interpreted about 251,000 digital breast tomosynthesis (DBT) and 2 million digital mammography screening examinations were included in this observational study that evaluated recall and cancer detection rates.
PMID: 32218042 [PubMed - as supplied by publisher]
Publication date: Available online 28 March 2020Source: International Journal of PharmaceuticsAuthor(s): Jing Wang, Maaike A.C. Bruin, Changpei Gan, Maria C. Lebre, Hilde Rosing, Jos H. Beijnen, Alfred H. Schinkel
The objective of this study is to assess the mutational spectrum of 14 additional FA genes (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FANCP, FANCQ, FANCR and FANCU) in a cohort of hereditary cancer patients, to compare with local cancer-free controls as well as GnomAD. A total of 1021 hereditary cancer patients and 194 controls were analyzed using our next generation custom sequencing panel. We identified 35 pathogenic variants in eight genes. A significant association with the risk of breast cancer/breast and ovarian cancer was found for carriers of FANCA mutations (odds ratio (OR) = 3.14 95% ...